Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy
Journal Title: Journal of Cancer Research & Therapy - Year 2013, Vol 1, Issue 8
Abstract
Background: The objective of this study is to provide certain data on clinical outcomes and their predictors of traditional maximum androgen blockade (MAB) in prostate cancer with bone metastasis. Methods: Subjects were patients with prostate adenocarcinoma with bone metastasis initiated to treat with MAB as a primary treatment without any local therapy at our hospital between January 2003 and December 2010. Time to prostate specific antigen (PSA) progression, overall survival (OS) time, and association of clinical factors and outcomes were retrospectively evaluated. Results: A total of 57 patients were evaluable. The median age was 70 years. The median primary PSA was 203 ng/ml. Luteinizing hormone-releasing hormone agonists had been administered in 96.5% of the patients. Bicalutamide had been chosen in 89.4 % of the patients as the initial antiandrogen. The median time to PSA progression with MAB was 11.3 months (95% confidence interval [CI], 10.4 to 13.0). The median OS was 47.3 months (95% CI, 30.7 to 81.0). Gleason score 9 or greater, decline of PSA level equal to or higher than 1.0 ng/ml with MAB, and time to PSA nadir equal to or shorter than six months after initiation of MAB were independent risk factors for time to PSA progression (P=0.010, P=0.005, and P=0.001; respectively). Time to PSA nadir longer than six months was the only independent predictor for longer OS (HR, 0.255 [95% CI, 0.109 to 0.597]; P=0.002). Conclusions: Initial time to PSA nadir should be emphasized for clinical outcome analyses in future studies on prostate cancer with bone metastasis.
Authors and Affiliations
Yamamoto Y, Nozawa M, Itami Y, Kobayashi Y, Saito Y, Shimizu N, Minami T, Hayashi T, Tsuji H, Yoshimura K, Ishii T, Uemura H
Keywords
Related Articles
- EP ID EP551739
- DOI 10.14312/2052-4994.2013-30
- Views 43
- Downloads 0
Antioxidant activity of some benzimidazole derivatives to definite tumor cell lines
A group of bis(benzimidazol-2-yl) amines have been already evaluated for cytotoxicity in vitro to human colorectal cancer cell line HT-29, breast cancer cells MDA-MB-231 and normal spleen cells and two of them (B1 and B2...
O-acetylated gangliosides: Structure, biosynthesis, immunogenicity, functions and their potential for cancer immunotherapy
Sialic acid O-acetylation is a developmentally regulated modification of gangliosides implicated in ontogeny and tumor progression. Their existence has been underestimated in the past because of their alkali-labile natur...
Factors associated with first-line bevacizumab use in advanced non-squamous non-small cell lung cancer
Introduction: Bevacizumab was approved for treatment of advanced non-squamous, non-small cell lung cancer (NSCLC) in the US in late 2006. Information on its uptake and patient and tumor factors associated with its use is...
Predictive and prognostic value of classification by immunohistochemical phenotypes in localised breast cancer treated with dose-dense adriamycin/cyclophosphamide
Introduction: Histopathologic subtyping according to the St. Gallen classification is predictive of response in women with breast cancer treated with neoadjuvant chemotherapy (NCT). Our aim was to confirm its predictive...
Some aspects of cancer biomarkers and their clinical application in solid tumors – revisited
Cancer biomarkers can be used for a variety of purposes related to screening, prediction, stratification, detection, diagnosis, prognosis, treatment design, and monitoring of a therapeutic response. One of the most impor...